Ligand Pharmaceuticals (LGND)
NASDAQ: LGND
· Real-Time Price · USD
105.14
0.60 (0.57%)
At close: May 19, 2025, 3:59 PM
106.00
0.82%
After-hours: May 19, 2025, 06:33 PM EDT
Ligand Pharmaceuticals Revenue Breakdown
| Period Ending | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | Dec 31, 2018 |
|---|---|---|---|---|---|---|---|
| Contract Revenue Revenue | 27.48M | 19.03M | 19.22M | 63.96M | 42.66M | 6.2M | 78.19M |
| Contract Revenue Revenue Growth | +44.37% | -0.99% | -69.94% | +49.91% | +588.24% | -92.07% | n/a |
| Financial Royalty Assets Revenue | 13.44M | 217K | 2.85M | 5.08M | 4.38M | 31.49M | 29.12M |
| Financial Royalty Assets Revenue Growth | +6095.39% | -92.38% | -43.96% | +16.13% | -86.10% | +8.12% | n/a |
| Intangible Royalty Assets Revenue | 95.33M | 28.37M | 104.5M | 164.25M | 109.96M | 46.98M | n/a |
| Intangible Royalty Assets Revenue Growth | +236.00% | -72.85% | -36.38% | +49.37% | +134.07% | n/a | n/a |
| License Fees Revenue | 1.94M | 28.37M | 16.43M | 48.93M | 21.8M | 5.17M | n/a |
| License Fees Revenue Growth | -93.15% | +72.69% | -66.42% | +124.40% | +321.64% | n/a | n/a |
| Material Sales, Captisol Revenue | 30.88M | 83.91M | 72.53M | 10.08M | n/a | 25.05M | n/a |
| Material Sales, Captisol Revenue Growth | -63.20% | +15.69% | +619.59% | n/a | n/a | n/a | n/a |
| Material Sales, Captisol, Core Revenue | 30.88M | 10.21M | 10.2M | 27.47M | n/a | 2.57M | n/a |
| Material Sales, Captisol, Core Revenue Growth | +202.42% | +0.15% | -62.88% | n/a | n/a | n/a | n/a |
| Royalty Revenue | 108.77M | 35.64M | 30.12M | 11.38M | n/a | n/a | n/a |
| Royalty Revenue Growth | +205.20% | +18.34% | +164.73% | n/a | n/a | n/a | n/a |
| Royalty, Evomela Revenue | 8.68M | 13.48M | 7.63M | 23.71M | n/a | n/a | n/a |
| Royalty, Evomela Revenue Growth | -35.59% | +76.56% | -67.81% | n/a | n/a | n/a | n/a |
| Royalty, Kyprolis Revenue | 38.38M | 615K | 1.12M | n/a | n/a | n/a | n/a |
| Royalty, Kyprolis Revenue Growth | +6140.16% | -44.94% | n/a | n/a | n/a | n/a | n/a |
| Royalty, Other Revenue | 8.95M | n/a | n/a | n/a | n/a | n/a | n/a |
| Royalty, Other Revenue Growth | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Service Revenue | 25.53M | n/a | n/a | n/a | n/a | n/a | n/a |
| Service Revenue Growth | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Operating Expense Breakdown
| Period Ending | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | Dec 31, 2018 | Sep 30, 2018 | Jun 30, 2018 | Mar 31, 2018 | Dec 31, 2017 | Sep 30, 2017 | Jun 30, 2017 | Mar 31, 2017 | Dec 31, 2016 | Sep 30, 2016 | Jun 30, 2016 | Mar 31, 2016 | Dec 31, 2015 | Sep 30, 2015 | Jun 30, 2015 | Mar 31, 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selling, General, and Administrative Revenue | 18.8M | 25.61M | 24.48M | 19.12M | 10.95M | 15.99M | 14.66M | 11.29M | 10.86M | 31.13M | 17.45M | 14.59M | 18.18M | 17.74M | 12.72M | 14.71M | 12.62M | 30.08M | 15.02M | 10.07M | 9.26M | 10.28M | 9.53M | 10.99M | 11.09M | 11.16M | 9.63M | 9.29M | 7.64M | 7.75M | 7.03M | 6.55M | 7.32M | 6.63M | 6.3M | 6.86M | 6.83M | 6.19M | 4.97M | 7.22M | 5.99M |
| Selling, General, and Administrative Revenue Growth | -26.57% | +4.62% | +27.99% | +74.62% | -31.52% | +9.12% | +29.85% | +3.98% | -65.13% | +78.45% | +19.61% | -19.77% | +2.50% | +39.46% | -13.55% | +16.60% | -58.06% | +100.28% | +49.17% | +8.69% | -9.86% | +7.90% | -13.36% | -0.85% | -0.67% | +15.88% | +3.65% | +21.60% | -1.37% | +10.20% | +7.38% | -10.56% | +10.50% | +5.09% | -8.13% | +0.56% | +10.26% | +24.52% | -31.20% | +20.54% | n/a |
| Research and Development Revenue | 50.09M | 4.42M | 5.67M | 5.35M | 5.97M | 5.49M | 5.53M | 6.85M | 6.66M | 9.2M | 22.04M | 19.12M | 20.31M | 18.24M | 16.94M | 15.95M | 17.88M | 21.92M | 12.85M | 12.73M | 11.89M | 18.66M | 13.74M | 12.21M | 11.29M | 8.84M | 5.48M | 6.13M | 7.41M | 8.63M | 4.76M | 4.82M | 8.67M | 6.41M | 6.3M | 4.51M | 4M | 2.87M | 2.54M | 4.01M | 3.96M |
| Research and Development Revenue Growth | +1031.86% | -22.03% | +6.00% | -10.33% | +8.80% | -0.80% | -19.29% | +2.87% | -27.55% | -58.26% | +15.26% | -5.86% | +11.31% | +7.70% | +6.17% | -10.77% | -18.42% | +70.51% | +0.95% | +7.07% | -36.29% | +35.82% | +12.52% | +8.18% | +27.70% | +61.23% | -10.63% | -17.17% | -14.20% | +81.40% | -1.31% | -44.40% | +35.35% | +1.63% | +39.89% | +12.56% | +39.51% | +13.08% | -36.71% | +1.21% | n/a |